{"id":410316,"date":"2021-01-07T08:03:45","date_gmt":"2021-01-07T13:03:45","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410316"},"modified":"2021-01-07T08:03:45","modified_gmt":"2021-01-07T13:03:45","slug":"logicbio-announces-extension-of-collaboration-with-childrens-medical-research-institute","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-announces-extension-of-collaboration-with-childrens-medical-research-institute\/","title":{"rendered":"LogicBio Announces Extension Of Collaboration With Children’s Medical Research Institute"},"content":{"rendered":"
\n

Collaboration seeks to develop next-generation viral vectors for gene therapy and gene editing applications in liver and two other tissues.<\/h2>\n

Program brings new levels of momentum to LogicBio as company plans for initiation of enrollment of SUNRISE Phase I\/II clinical trial in treatment of methylmalonic acidemia (MMA) and other milestones.<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LEXINGTON, Mass.<\/span>, Jan. 7, 2021<\/span> \/PRNewswire\/ —\u00a0LogicBio Therapeutics, Inc. (LogicBio – Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the expansion of the Company’s research partnership with Children’s Medical Research Institute (CMRI) to develop next-generation adeno-associated virus (AAV) vectors for a range of gene therapy and gene editing applications in the treatment of serious diseases of the liver and two other tissues.<\/p>\n

“I am very pleased to announce the expansion of our collaboration with CMRI, which over the past two years has already led to many important advances in our liver-targeting AAV vectors research,” said Frederic Chereau<\/span>, LogicBio President and CEO. “We now look forward to advancing the initial discovery efforts and to the expansion of our research into AAV capsids, the cell-targeting protein shell of viral vectors, for two additional tissues beyond the liver. We believe these broadening efforts will allow us to further expand the LogicBio pipeline and position us to explore a greater range of partnership opportunities.”<\/p>\n

New data highlighting the advantages of next-generation AAV capsids developed through the collaboration have been presented at multiple leading scientific conferences including the European Society of Gene and Cell Therapy and the American Society of Gene and Cell Therapy. To design next-generation AAV capsids, the CMRI team applies innovative genetic and molecular biology techniques including\u00a0bioinformatics, machine learning and other computational methods. CMRI is also developing unique clinically predictive models to select and assess novel capsids. The Company anticipates that expansion of this collaboration will position LogicBio to advance research focusing on areas of unmet need in liver health and in two additional tissues to be announced in the near future.<\/p>\n

The Company believes that these novel AAV capsids have broad potential applications in gene therapy and for gene editing platforms such as GeneRide\u2122, LogicBio’s proprietary gene editing technology that harnesses a cell’s natural DNA repair process, known as homologous recombination, to insert a corrective copy of a gene at a precise spot in a patient’s genome.<\/p>\n

“The expansion of our research collaboration with CMRI comes at a very exciting time for LogicBio as we are poised to enroll the first patients in our SUNRISE Phase I\/II clinical trial<\/a> for LB-001 in the treatment of methylmalonic acidemia,” Mr. Chereau added. “In addition, we are also advancing research with our investigational therapy LB-301 for the treatment of Crigler-Najjar along with our partners from Takeda. We have learned a great deal about the potential applications of GeneRide in these past four years and look forward to publishing additional proof of concept data and announcing our new target indications in 2021.”<\/p>\n

In August 2020<\/span>, LogicBio announced that the FDA authorized the company to initiate the SUNRISE clinical trial and that the study would be open to patients with methylmalonic acidemia\u00a0(MMA) as young as three years old, with the opportunity to treat patients as young as six months old as the trial progresses. Early treatment in MMA patients can allow for intervention prior to development or advance of nonreversible symptoms.\u00a0 <\/p>\n

“The approval of our IND by the FDA for the SUNRISE trial to treat very young patients is a reflection of the quality of our pre-clinical data and the design of our clinical trial,” said Dr. Daniel Gruskin<\/span>, LogicBio SVP of Clinical Development.<\/p>\n

LB-001 was granted Fast Track designation by the FDA in November 2020<\/span> and Rare Pediatric Disease designation in July 2019<\/span>.<\/p>\n

Upcoming LogicBio investor conference presentations: <\/p>\n